This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tamalet, C.
Right arrow Articles by Lafeuillade, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tamalet, C.
Right arrow Articles by Lafeuillade, A.

 Previous Article

Antimicrobial Agents and Chemotherapy, November 2004, p. 4493-4494, Vol. 48, No. 11
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.11.4493-4494.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Uncommon Association of T69 3-Base-Pair Insertion Plus Q151M Multidrug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase


arrow
LETTER
 
The reverse transcriptase (RT) Q151M complex which includes a cluster of five mutations (A62V, V75I, F77L, F116Y, and Q151M) and the codon 69 insertion are two independent multinucleoside resistance (MNR) pathways. Up to now, Q151M and F116Y mutations were never found to be associated with a ß3-ß4 insertion (4, 5, 6, 7, 8).

To the best of our knowledge, this is the first report of the coselection of a T69 insertion with F116Y and Q151M mutations. The patient was a 41-year-old homosexual individual who began therapy with zidovudine (ZDV) in 1997 followed by a 12-month administration of combivir and then dideoxyinosine (ddI) plus stavudine (d4T) for 24 months. HIV-1 RNA in plasma rose to 16,200 copies/ml in December 2001 (Fig. 1). Then, the patient received a triple therapy including tenofovir disoproxil fumarate (TDF), efavirenz (EFV), and lopinavir/r (LPV/r). The virus drug resistance was evaluated as previously described (5) from sequential plasma samples. The cDNA derived from plasma HIV-1 RNA was sequenced and cloned in PGEM-1 easy plasmid. The first investigated specimen (September 2000) showed a RT T69S-T insertion associated with nucleoside-associated mutations (NAMs) D67N, K70R, and K219Q. Under ddI-D4T treatment, Q151M and F116Y mutations appeared in December 2001 in the same genetic background consisting of the previous NAMs (D67N, K70R, and K219Q), plus the insertion evolving from T69S-T to T69T-T. In December 2001, the clonal analysis (100% of the 23 clones tested) of the plasma viral RNA revealed the colinearity of these genetic changes; the phenotypic analysis (recombinant virus assay antivirogram) showed reduced susceptibility to ZDV, ddI, dideoxycytosine (ddC), and d4T (with phenotypic susceptibility changes in the 50% inhibitory concentration [IC50] of 8.6, 6.7, 8.2 and 10.4, respectively), a normal susceptibility to 3TC and ABC (phenotypic susceptibility change in IC50 of 3.1 and 1.6, respectively), and a phenotypic susceptibility change in IC50 of 1.8 for TDF which might be clinically significant because the clinical cutoff for a reduced response to this compound is 1.4-fold (1, 2). After 5 months of a TDF-EFV-LPV/r regimen, plasma viral load decreased to <50 copies/ml and CD4 count increased to ≥400/mm3 until the end of the study.



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1. Immunologic-virologic profile of the patient over time. *, the number in parentheses is the percentage of clones with the mutated amino acid. **, HIV-1 RNA is expressed in copies per milliliter.

Our clonal analysis showed that HIV-1 can acquire insertions and then multidrug resistance mutations in the same genome. Furthermore, sequencing of the bulk plasma HIV-1 RNA isolate of the 03/02 time point confirmed this double MNR genotype. It should be noted that this double MNR virus was associated with the cluster of NAMs D67N, K70R, and K219Q, classically associated with lower levels of resistance to TDF than mutations at positions 41, 210, and 215 (3).

The clinical consequences of this double MNR pattern, in particular how it could influence the virological response to nucleosides or nucleotide RT inhibitors, have yet to be determined. Interestingly, structural analysis based on molecular modeling of the RT, using the crystallized wild-type RT as template (data not shown), indicated that there was no steric clash between the side chains of the mutated residues suggesting that the Q151M/insertion 69 mutant may be functional. These data are consistent with the observed replication of the patient's viruses and suggest that HIV-1 RT can accommodate this uncommon association of two MNR genotypes without loss of function.


arrow
REFERENCES
 
    1
  1. Lu, B., N. S. Hellmann, M. Bates, K. Dawson, J. Rooney, and M. D. Miller. 2002. Determination of clinical cut-offs for reduced response to tenofovir DF therapy in antiretroviral-experienced patients. Antiviral Ther. 7 (Suppl. 1):S137.
    2. 2
  2. Miller, M. D., N. A. Margot, K. Hertogs, B. Larder, and V. Miller. 2001. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 20:1025-1028.[CrossRef][Medline]
    3. 3
  3. Miller, M. D., N. Margot, B. Lu, L. Zhong, S. S. Chen, A. Cheng, and M. Wulfsohn. 2004. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. 189:837-846.[CrossRef][Medline]
    4. 4
  4. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kaojima, M. L. Alcaide, S. Chockechuchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.[Abstract/Free Full Text]
    5. 5
  5. Tamalet, C., N. Yahi, C. Tourres, P. Colson, A. M. Quinson, I. Poizot-Martin, C. Dhiver, and J. Fantini. 2000. Multidrug resistance genotypes (insertions in the ß3-ß4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations. Virology 270:310-316.[CrossRef][Medline]
    6. 6
  6. Van Vaerenbergh, K., K. Van Laethem, J. Albert, C. A. Boucher, B. Clotet, M. Floridia, J. Gerstoft, B. Hejdeman, C. Nielsen, C. Pannecouque, L. Perrin, M. F. Pirillo, L. Ruiz, J. C. Schmit, F. Schneider, A. Schoolmeester, R. Schuurman, H. J. Stellbrink, L. Stuyver, J. Van Lunzen, B. Van Remoortel, E. Van Wijngaerden, S. Vella, M. Witvrouw, S. Yerly, E. De Clercq, J. Destmyer, and A. M. Vandamme. 2000. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob. Agents Chemother. 44:2109-2117.[Abstract/Free Full Text]
    7. 7
  7. Winters, M. A., K. L. Coolley, A. Girard, D. J. Levee, H. Hamdan, R. W. Shafer, D. A. Katzenstein, and T. C. Merigan. 1998. A 6-basepair deletion in the reverse transcriptase gene of HIV-1 confers resistance to multiple nucleoside inhibitors. J. Clin. Investig. 102:1769-1775.[Medline]
    8. 8
  8. Winters, M. A., K. L. Coolley, P. Cheng, Y. Agirard, H. Hamdan, L. C. Kovari, and T. C. Merigan. 2000. Genotypic, phenotypic, and modeling studies of a deletion in the ß3-ß4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. J. Virol. 74:10707-10713.[Abstract/Free Full Text]
Catherine Tamalet*
Mireille Henry
Philippe Colson
Virology Laboratory
Timone University Hospital and CNRS UMR 6020 IFR 48 Université de la Méditerranée
13385 Marseille Cedex 5, France

Nouara Yahi
Faculté des Sciences, St. Jérôme
Marseille, France

Cecile Poggi
Alain Lafeuillade
Chalucet Hospital
Rue Chalucet
83000 Toulon, France

* Phone: 33 491 388 522, Fax: 33 491 779 266, E-mail: ctamalet{at}ap-hm.fr

Antimicrobial Agents and Chemotherapy, November 2004, p. 4493-4494, Vol. 48, No. 11
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.11.4493-4494.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tamalet, C.
Right arrow Articles by Lafeuillade, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tamalet, C.
Right arrow Articles by Lafeuillade, A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»